A plant flavonoid that may slow the age-related NAD+ drain by inhibiting the CD38 enzyme.
Biologically interesting but human evidence is thin. Very safe at supplement doses (50 to 500 mg/day). Reasonable as a low-cost add-on to a NAD+ strategy, not a lead actor.
Apigenin (Apigenin (4',5,7-trihydroxyflavone)) is a flavonoid / cd38 inhibitor with evidence grade D, meaning it is primarily supported by animal studies. We track 3 products containing Apigenin. Typical doses range from 50 to 250 mg per serving. The top-ranked product scores 5.9 out of 10 on our composite scale (dose, evidence, price, testing, transparency). Prices range up to $55.00 per month.
| Product | Brand | Dose | Price/mo | 3rd-party tested | Score |
|---|---|---|---|---|---|
| Apigenin Supplement | Double Wood Supplements | 50 mg | $24.95 | Yes | 5.9 |
| Senolytic Activator | Life Extension | 50 mg | $19.89 | Yes | 5.7 |
| Pure Apigenin | DoNotAge | 250 mg | $55.00 | Yes | 5.5 |
Scores are editorial judgments, not a scientific standard. See how we score.
Apigenin is a flavonoid found in parsley, chamomile, celery, and grapefruit. In cell studies it blocks an enzyme called CD38 that consumes NAD+ as we age.
The theory: less CD38 activity means less NAD+ destruction, so your NAD+ pool stays higher for longer. Direct human trials on aging endpoints are not yet available; most evidence is preclinical or mechanistic.
Biologically interesting but human evidence is thin. Very safe at supplement doses (50 to 500 mg/day). Reasonable as a low-cost add-on to a NAD+ strategy, not a lead actor.
4',5,7-Trihydroxyflavone. Non-competitive CD38 inhibitor; also modulates NF-κB, mTOR, and estrogen receptor β signalling in vitro.
Preclinical data (Escande 2013; Chini 2020) show CD38 inhibition and elevated NAD+ in mouse tissues. Senolytic activity demonstrated in vitro alongside fisetin/quercetin. No published human RCT on healthspan endpoints as of 2026.
~90 min in humans; low oral bioavailability.
Bioavailability is low without a fat carrier or phytosome form; grapefruit-derived apigenin retains CYP3A4 interaction risk.
When a product exceeds the UL or contains an ingredient with clinically significant interactions, a "Review advised" flag appears on its product page and links here.
The trial dose above is our editorial pick from the published human trials for this ingredient. We choose the dose that the best-available studies used on the endpoint most relevant to longevity. The range shows the lowest and highest doses tested in published trials. The landmark studies below are the papers we read to set it. You can click through and check our work.
When new trials publish, our automated sweeps flag them. If a new study materially changes the dose, we update it through editorial review and record the old dose, new dose, and the triggering study in every affected product's recommendation history. The dose is never changed automatically.
Regulatory events, evidence grade changes, and key research milestones for Apigenin, most recent first. Studies link to the paper; regulatory entries name and link the responsible authority.
Apigenin inhibited CD38 in vitro and raised NAD+ in mouse tissues, improving metabolic markers.
Read study →CD38 identified as major NAD+ase driving NAD+ decline with aging, pharmacological CD38 inhibition (including flavonoids like apigenin) reversed tissue NAD+ loss in mice.
Read study →All products in our catalog that contain Apigenin, ranked by our overall score. Ranking is editorial, never paid.
Double Wood SupplementsStatus as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.
Editorial score, not proof that this product works. Research-dose calculations are not dosing advice.
Life ExtensionMulti-ingredient bundle
Status as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.
Editorial score, not proof that this product works. Research-dose calculations are not dosing advice.
DoNotAgeStatus as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.
Editorial score, not proof that this product works. Research-dose calculations are not dosing advice.
Molecules in the same class, plus the actives most often formulated alongside Apigenin in our catalogue.
See Apigenin in context: the mechanism it acts through, the biomarker it moves, the products that dose it, and the trials that tested it.
View Apigenin on the Longevity Map →Apigenin is a flavonoid found in parsley, chamomile, celery, and grapefruit. In cell studies it blocks an enzyme called CD38 that consumes NAD+ as we age.
The trial dose in published human studies is 50 mg per day, with a range of 25 to 500 mg per day. Always consult a qualified clinician before starting any supplement.
No formal UL. Generally recognized as safe with no reported toxicity from typical dietary or supplemental intake (e.g., 50 mg/day); sedation/muscle relaxation only reported at extreme experimental doses.
We track 3 products containing Apigenin. The top-ranked product scores 5.9 out of 10 on our composite scale, which evaluates dose, evidence, price, third-party testing, and transparency. See the comparison table above. Scores are editorial judgments, not a scientific standard.
Apigenin has evidence grade D, meaning it is primarily supported by animal studies. Grade A means replicated human RCTs with hard endpoints. Grade B means human RCTs with biomarker outcomes. Grade C means mixed or small human trials. See our evidence grading methodology.
Evidence grades are reviewed when new human RCTs are published. Product counts update automatically as new products are added. Dose ranges reflect published trial data, not brand recommendations. Read how we verify.